Pinnacle Medicines | $89,000,000 | (Mar 27, 2026)
CurrentClient | $1,250,000 | (Mar 27, 2026)
Mirage | $75,000,000 | (Mar 27, 2026)
Foresight Diagnostics Inc.
United States
- Aurora, CO
- 28/04/2023
- Series B
- $58,750,000
Foresight Diagnostics is a precision medicine company developing a novel liquid biopsy test for the measurement of minimal residual disease (MRD) for aid in patient management that is funded by leading diagnostics VC firms in Silicon Valley. Foresight’s cell-free DNA testing platform was developed in the labs of two prominent professors at Stanford University and is backed by several major peer-reviewed publications. The company has garnered significant partnering interest from multiple pharmaceutical companies in oncology and is poised for rapid growth. Foresight Diagnostics is headquartered in Aurora, Colorado.
- Industry Biotechnology Research
- Website https://www.foresight-dx.com/
- LinkedIn https://www.linkedin.com/company/foresight-diagnostics-inc/
Related People
Jake ChabonCo Founder
United States -
Denver, Colorado
I am molecular biologist and bioinformatic scientist with a passion for entrepreneurship. I completed my graduate and postdoctoral training at Stanford University where my research was focused on developing novel blood based cancer diagnostic assays. I am now the CEO & Co-founder of Foresight Diagnostics, a venture-backed molecular diagnostics company that is developing non-invasive cancer detection technologies. Foresight’s unique cell-free DNA testing platform enables the ultra-sensitive detection of tumor-derived DNA in the bloodstream, leading to more personalized and effective cancer treatment strategies for patients.
SIGMAS | $1,000,000 | (Mar 27, 2026)
VITL | $7,500,000 | (Mar 27, 2026)
Payy | $6,000,000 | (Mar 27, 2026)
Conntour | $7,000,000 | (Mar 27, 2026)
Terrestrial | $50,000,000 | (Mar 27, 2026)
Krane | $9,000,000 | (Mar 26, 2026)
Zalos (YC F25) | $3,600,000 | (Mar 26, 2026)